Research Paper Volume 16, Issue 13 pp 11072—11089
AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity
Figure 4. AK7 can be used as a prognostic indicator and a predictor of immunotherapy effect in ccRCC patients. (A) In pancarcinoma, patients with high expression of AK7 have a better prognosis than those with low expression. (B) In ccRCC, patients with high expression of AK7 had longer OS than those with low expression. (C) In ccRCC at stage 4, patients with high expression of AK7 had longer OS than those with low expression. (D–F) In patients treated with anti-PD1 (D), anti-PD-L1 (E), and anti-CTLA-4 (F), high expression of AK7 has a better prognosis. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.